Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ryvu TherapeuticsWAR:RVU -1.80%66 Current Ratio is 2.26 as of Mar. 2026, which is 30% below its 10-year median of 3.21. GuruFocus rates WAR:RVU with a GF Score™ of 66/100 and a GF Value™ of zł45.84 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Ryvu Therapeutics ranks worse than 64.78% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Ryvu Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 2.26.
Ryvu Therapeutics has a current ratio of 2.26. It generally indicates good short-term financial strength.
The historical rank and industry rank for Ryvu Therapeutics's Current Ratio or its related term are showing as below:
WAR:RVU'
s Current Ratio Range Over the Past 10 Years
Min: 1.83 Med: 3.21 Max: 9.1
Current: 2.26
During the past 13 years, Ryvu Therapeutics's highest Current Ratio was 9.10. The lowest was 1.83. And the median was 3.21.
WAR:RVU's Current Ratio is ranked worse than 64.78% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs WAR:RVU: 2.26
Ryvu Therapeutics (WAR:RVU) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Ryvu Therapeutics Current Ratio Related Terms
Ryvu Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Ryvu Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:RVU vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Ryvu Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryvu Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Ryvu Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryvu Therapeutics (WAR:RVU) has a Current Ratio of 2.26 as of Mar. 2026. This is 30% below median its historical median of 3.21. Over the past decade, Ryvu Therapeutics' Current Ratio has ranged from 1.83 to 9.10. According to the industry distribution chart, Ryvu Therapeutics ranks #914 out of 1411 companies in the Biotechnology industry, placing it in the top 64.8%.
Is Ryvu Therapeutics' Current Ratio too high?
Ryvu Therapeutics' current Current Ratio of 2.26 is 30% below median its 10-year median of 3.21. Over the past 10 years, this metric has ranged from a low of 1.83 to a high of 9.10. The Biotechnology industry median Current Ratio is 3.88. Ryvu Therapeutics' value of 2.26 is 41.8% below this industry median. Based on the distribution chart, Ryvu Therapeutics ranks #914 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ryvu Therapeutics has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ryvu Therapeutics ranks #914 out of 1411 companies for Current Ratio. This places Ryvu Therapeutics in the lower half of its industry. The industry median Current Ratio is 3.88. Ryvu Therapeutics' value of 2.26 is 41.8% below this benchmark. Historically, Ryvu Therapeutics' own Current Ratio has ranged from 1.83 to 9.10 over the past decade. While the company's 10-year median is 3.21 vs. the industry median of 3.88, Ryvu Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ryvu Therapeutics's current Current Ratio of 2.26 is 41.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryvu Therapeutics's current Current Ratio is 2.26, which is 30% below median its own 10-year median of 3.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ryvu Therapeutics (WAR:RVU) is currently considered Possible Value Trap. The stock's GF Value™ is zł45.84, compared to a current price of zł15.30 — trading 66.6% below its estimated fair value. The current Current Ratio is 2.26, which is 30% below median its 10-year median of 3.21 and 41.8% below the Biotechnology industry median of 3.88. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Ryvu Therapeutics (WAR:RVU), the current Current Ratio is 2.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryvu Therapeutics (WAR:RVU) Overvalued in 2026?
Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued.
The current stock price of zł15.30 is trading 66.6% below its estimated GF Value™ of zł45.84.
GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.
Key valuation signals for WAR:RVU:
Current Ratio: 2.26 (30% below median its 10-year median of 3.21)
GF Value™: zł45.84 vs. price of zł15.30 (66.6% below fair value)
Industry Position: 41.8% below the Biotechnology median (#914 of 1411)
No single metric tells the full story. See the WAR:RVU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score
Get the complete analysis for WAR:RVU
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:RVU has been successfully added to your 
